Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus

Annals of Internal Medicine

Volumn 154, Issue 12, 2011, Pages 797-805

  Taveira Dasilva, Angelo M ^a   Hathaway, Olanda ^a   Stylianou, Mario ^a   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; RAPAMYCIN;

ACNE; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHYLOUS ASCITES; CLINICAL ARTICLE; DIARRHEA; DRUG ERUPTION; FORCED EXPIRATORY VOLUME; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LYMPHANGIOLEIOMYOMATOSIS; MENORRHAGIA; MENSTRUAL IRREGULARITY; MOUTH ULCER; NEUTROPENIA; OBSERVATIONAL STUDY; PLEURA FLUID; PRIORITY JOURNAL; SKIN BRUISING; SKIN INFECTION; TREATMENT OUTCOME;

EID: 79959639375     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-154-12-201106210-00007     Document Type: Article

References (45)

1. Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, et al.; NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173: 105-111. [PMID: 16210669]
2. McCormack FX. Lymphangioleiomyomatosis:a clinical update. Chest. 2008; 133:507-516. [PMID: 18252917]
3. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphan-gioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc. 2000;75:591-594. [PMID: 10852420]
4. Moss J, Avila NA, Barnes PM, Litzenberger RA, Bechtle J, Brooks PG, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med. 2001;164: 669-671. [PMID: 11520735]
5. Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, et al. Mutational and radiographic analysis of pulmonary disease consistent with lym- phangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med. 2001;164:661-668. [PMID: 11520734]
6. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125-127. [PMID: 2039137]
7. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305-1315. [PMID: 8269512]
8. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 1998;62:810-815. [PMID: 9529362]
9. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyoma-tosis. Proc Natl Acad Sci U S A. 2000;97:6085-690. [PMID: 10823953]
10. Matsui K, Tatsuguchi A, Valencia J, Yu Z, Bechtle J, Beasley MB, et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol. 2000;31:1242-1248. [PMID: 11070117]
11. Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J. Lymphangioleiomyoma-tosis: abdominopelvic CT and US findings. Radiology. 2000;216:147-153. [PMID: 10887241]
12. Ryu JH, Doerr CH, Fisher SD, Olson EJ, Sahn SA. Chylothorax in lymp- hangioleiomyomatosis. Chest. 2003;123:623-627. [PMID: 12576391]
13. Almoosa KF, McCormack FX, Sahn SA. Pleural disease in lymphangioleio-myomatosis. Clin Chest Med. 2006;27:355-368. [PMID: 16716823]
14. Glasgow CG, Taveira-DaSilva A, Pacheco-Rodriguez G, Steagall WK, Tsu-kada K, Cai X, et al. Involvement of lymphatics in lymphangioleiomyomatosis. Lymphat Res Biol. 2009;7:221-228. [PMID: 20143921]
15. Jaiswal VR, Baird J, Fleming J, Miller DS, Sharma S, Molberg K. Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature. Arch Pathol Lab Med. 2003;127:879-882. [PMID: 12823048]
16. Lu HC, Wang J, Tsang YM, Lin MC, Li YW. Lymphangioleiomyomatosis initially presenting with abdominal pain: a case report. Clin Imaging. 2003;27: 166-170. [PMID: 12727053]
17. Wong YY, Yeung TK, Chu WC. Atypical presentation of lymphangioleio-myomatosis as acute abdomen: CT diagnosis. AJR Am J Roentgenol. 2003;181: 284-285. [PMID: 12818883]
18. Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int. 2004;66: 924-934. [PMID: 15327383]
19. Sooriakumaran P, Gibbs P, Coughlin G, Attard V, Elmslie F, Kingswood C, et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int. 2010;105:101-106. [PMID: 19493268]
20. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest. 2004;126:1867-1874. [PMID: 15596686]
21. Cohen MM, Pollock-BarZiv S, Johnson SR. Emerging clinical picture of lymphangioleiomyomatosis. Thorax. 2005;60:875-879. [PMID: 16055626]
22. Goncharova EA, Krymskaya VP. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges. J Cell Biochem. 2008;103:369-382. [PMID: 17541983]
23. Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle. 2009;8:403-413. [PMID: 19177005]
24. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99:13571-13576. [PMID: 12271141]
25. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003;13: 1259-1268. [PMID: 12906785]
26. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 2002;277:30958-30967. [PMID: 12045200]
27. Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG, et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol. 2000;2:281-287. [PMID: 10806479]
28. El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res. 2004;64:3436-3443. [PMID: 15150095]
29. Kenerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res. 2005;57:67-75. [PMID:15557109]
30. Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer. 2005;42:213-227. [PMID: 15578690]
31. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphan-gioleiomyomatosis. N Engl J Med. 2008;358:140-151. [PMID: 18184959]
32. Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphan-gioleiomyomatosis [Letter]. N Engl J Med. 2008;358:200-203. [PMID: 18184971]
33. Taillé C, Debray MP, Crestani B. Sirolimus treatment for pulmonary lym-phangioleiomyomatosis [Letter]. Ann Intern Med. 2007;146:687-688. [PMID: 17470843]
34. Sugimoto R, Nakao A, Yamane M, Toyooka S, Okazaki M, Aoe M, et al. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyoma-tosis after living-donor lobar lung transplantation. J Heart Lung Transplant. 2008;27:921-924. [PMID: 18656809]
35. Ohara T, Oto T, Miyoshi K, Tao H, Yamane M, Toyooka S, et al. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyo-matosis. Ann Thorac Surg. 2008;86:e7-e8. [PMID: 19021963]
36. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801-1811. [PMID: 21047224]
37. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al.; National Institutes of Health Rare Lung Diseases Consortium. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364: 1595-606. [PMID: 21410393]
38. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005; 26:319-338. [PMID: 16055882]
39. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720-735. [PMID: 16204605]
40. Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax. 2004;59:800-803. [PMID: 15333859]
41. Lazor R, Valeyre D, Lacronique J, Wallaert B, Urban T, Cordier JF.; Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires. Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyo-matosis. Respir Med. 2004;98:536-541. [PMID: 15191039]
42. Hayashida M, Seyama K, Inoue Y, Fujimoto K, Kubo K.; Respiratory Failure Research Group of the Japanese Ministry of Health, Labor, and Welfare. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology. 2007;12:523-530. [PMID: 17587419]
43. Gupta D, Ross K, Piacentino V, Stepnowski D, McClurken JB, Furu-kawa S, et al. Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax. Ann Thorac Surg. 2004;78:e9-12. [PMID: 15223489]
44. Mikroulis D, Didilis V, Bitzikas G, Bougioukas G. Octreotide in the treatment of chylothorax [Letter]. Chest. 2002;121:2079-2080. [PMID: 12065385]
45. Makrilakis K, Pavlatos S, Giannikopoulos G, Toubanakis C, Katsilambros N. Successful octreotide treatment of chylous pleural effusion and lymphedema in the yellow nail syndrome [Letter]. Ann Intern Med. 2004;141:246-247. [PMID: 15289232]